Details of the Drug

General Information of Drug (ID: DMIF7KG)

Drug Name

PMID27977313-Compound-29

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

217.31

Logarithm of the Partition Coefficient (xlogp)

2.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Coagulation factor decreased	Not Available	F10	OT2BLK17	[1]
Coagulation factor decreased	Not Available	SERPINF2	OTZGAF8B	[1]
Haemorrhagic diathesis	Not Available	pla	OT47J5C9	[1]
Haemorrhagic diathesis	Not Available	HRG	OTPLUFOG	[1]
Lipid metabolism disorder	Not Available	VLDLR	OTZBTD8C	[1]
Lipids abnormal	Not Available	APOB	OTS88GMA	[1]
-----------


⏷ Show the Full List of 6 ADR Information of This Drug

Chemical Identifiers

Formula: C14H19NO
IUPAC Name: 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one
Canonical SMILES: CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C
InChI: InChI=1S/C14H19NO/c1-10-6-7-13(11(2)8-10)14(16)12(3)9-15(4)5/h6-8H,3,9H2,1-2,4-5H3
InChIKey: QXLQZLBNPTZMRK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 436058
CAS Number: 116218-49-6
TTD ID: D0PT8T
ACDINA ID: D01322

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytoplasmic thioredoxin reductase (TXNRD1)	TTR7UJ3	TRXR1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-2-antiplasmin (SERPINF2)	OTZGAF8B	A2AP_HUMAN	Drug Response	[1]
Apolipoprotein B (APOB)	OTS88GMA	APOB_CHICK	Drug Response	[1]
Coagulation factor X (F10)	OT2BLK17	FA10_HUMAN	Drug Response	[1]
Histidine-rich glycoprotein (HRG)	OTPLUFOG	HRG_HUMAN	Drug Response	[1]
Plasminogen activator (pla)	OT47J5C9	PLA_YERPE	Drug Response	[1]
Very low-density lipoprotein receptor	OTZBTD8C	VLDLR_HUMAN	Drug Response	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as PMID27977313-Compound-29

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
PMID28454500-Compound-96	DM2A75P	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and PMID28454500-Compound-96.	Discovery agent [N.A.]	[3]
-----------

Coadministration of a Drug Treating the Disease Different from PMID27977313-Compound-29 (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[4]
Tretinoin	DM49DUI	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tretinoin.	Acne vulgaris [ED80]	[3]
Isotretinoin	DM4QTBN	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Isotretinoin.	Acne vulgaris [ED80]	[3]
Nicotinamide	DMUPE07	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nicotinamide.	Acquired cutaneous blood vessel malformation [EF20]	[5]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Thioguanine.	Acute myeloid leukaemia [2A60]	[6]
Chlorzoxazone	DMCYVDT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Chlorzoxazone.	Acute pain [MG31]	[3]
Oxandrolone	DMU9MYJ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxandrolone.	Alcoholic liver disease [DB94]	[3]
Tacrine	DM51FY6	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tacrine.	Alzheimer disease [8A20]	[3]
Dronedarone	DMA8FS5	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Dronedarone.	Angina pectoris [BA40]	[3]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[7]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxymetholone.	Aplastic anaemia [3A70]	[3]
Voriconazole	DMAOL2S	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Voriconazole.	Aspergillosis [1F20]	[3]
Posaconazole	DMUL5EW	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Posaconazole.	Aspergillosis [1F20]	[3]
Zafirlukast	DMHNQOG	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zafirlukast.	Asthma [CA23]	[3]
Zileuton	DMVRIC2	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zileuton.	Asthma [CA23]	[3]
Atomoxetine	DM5L6HI	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[3]
Clavulanate	DM2FGRT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Clavulanate.	Bacterial infection [1A00-1C4Z]	[5]
Trovafloxacin	DM6AN32	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[3]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[3]
Oxytetracycline	DMOVH1M	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxytetracycline.	Bacterial infection [1A00-1C4Z]	[3]
Levofloxacin	DMS60RB	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[3]
Moxifloxacin	DMU8V4S	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[3]
Minocycline	DMVN5OH	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Minocycline.	Bacterial infection [1A00-1C4Z]	[3]
Telithromycin	DMZ4P3A	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Telithromycin.	Bacterial infection [1A00-1C4Z]	[3]
Tetracycline	DMZA017	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tetracycline.	Bacterial infection [1A00-1C4Z]	[3]
Temozolomide	DMKECZD	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Temozolomide.	Brain cancer [2A00]	[3]
Lomustine	DMMWSUL	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lomustine.	Brain cancer [2A00]	[3]
Lapatinib	DM3BH1Y	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lapatinib.	Breast cancer [2C60-2C6Y]	[3]
Pralatrexate	DMAO80I	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pralatrexate.	Breast cancer [2C60-2C6Y]	[3]
Tucatinib	DMBESUA	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tucatinib.	Breast cancer [2C60-2C6Y]	[3]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tamoxifen.	Breast cancer [2C60-2C6Y]	[3]
Bosutinib	DMTI8YE	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bosutinib.	Breast cancer [2C60-2C6Y]	[3]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[5]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[3]
Demeclocycline	DMZEPFJ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Demeclocycline.	Bronchitis [CA20]	[3]
Atorvastatin	DMF28YC	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Atorvastatin.	Cardiovascular disease [BA00-BE2Z]	[3]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[3]
Macitentan	DMP79A1	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Macitentan.	Cardiovascular disease [BA00-BE2Z]	[3]
Chenodiol	DMQ8JIK	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Chenodiol.	Cholelithiasis [DC11]	[3]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Phenylbutazone.	Chronic pain [MG30]	[8]
Ketoprofen	DMRKXPT	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ketoprofen.	Chronic pain [MG30]	[8]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Anisindione.	Coagulation defect [3B10]	[8]
Regorafenib	DMHSY1I	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Regorafenib.	Colorectal cancer [2B91]	[3]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Oxaliplatin.	Colorectal cancer [2B91]	[3]
Intedanib	DMSTA36	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Intedanib.	Colorectal cancer [2B91]	[3]
Drospirenone	DM1A9W3	Moderate	Decreased metabolism of PMID27977313-Compound-29 caused by Drospirenone mediated hepatotoxicity.	Contraceptive management [QA21]	[4]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of PMID27977313-Compound-29 caused by Levonorgestrel mediated hepatotoxicity.	Contraceptive management [QA21]	[4]
Desogestrel	DM27U4Y	Moderate	Decreased metabolism of PMID27977313-Compound-29 caused by Desogestrel mediated hepatotoxicity.	Contraceptive management [QA21]	[4]
Norgestimate	DMYP4XC	Moderate	Decreased metabolism of PMID27977313-Compound-29 caused by Norgestimate mediated hepatotoxicity.	Contraceptive management [QA21]	[4]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ardeparin.	Coronary thrombosis [BA43]	[8]
Pasireotide	DMHM7JS	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pasireotide.	Cushing syndrome [5A70]	[3]
Ivacaftor	DMZC1HS	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ivacaftor.	Cystic fibrosis [CA25]	[3]
Ethanol	DMDRQZU	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ethanol.	Cystitis [GC00]	[3]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Danaparoid.	Deep vein thrombosis [BD71]	[8]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Rivaroxaban.	Deep vein thrombosis [BD71]	[8]
Nefazodone	DM4ZS8M	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nefazodone.	Depression [6A70-6A7Z]	[3]
Duloxetine	DM9BI7M	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Duloxetine.	Depression [6A70-6A7Z]	[3]
Milnacipran	DMBFE74	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Milnacipran.	Depression [6A70-6A7Z]	[3]
Polatuzumab vedotin	DMF6Y0L	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[3]
Felbamate	DM1V5ZS	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[3]
Mephenytoin	DM5UGDK	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[3]
Valproate	DMCFE9I	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Valproate.	Epilepsy/seizure [8A61-8A6Z]	[3]
Phenytoin	DMNOKBV	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Phenytoin.	Epilepsy/seizure [8A61-8A6Z]	[3]
Fosphenytoin	DMOX3LB	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[3]
Carbamazepine	DMZOLBI	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[3]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Cannabidiol.	Epileptic encephalopathy [8A62]	[9]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Mefenamic acid.	Female pelvic pain [GA34]	[8]
Dantrolene	DM1D8XY	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Dantrolene.	Fever [MG26]	[3]
Itraconazole	DMCR1MV	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Itraconazole.	Fungal infection [1F29-1F2F]	[3]
Caspofungin	DMGQIPT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Caspofungin.	Fungal infection [1F29-1F2F]	[3]
Terbinafine	DMI6HUW	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Terbinafine.	Fungal infection [1F29-1F2F]	[3]
Clotrimazole	DMMFCIH	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Clotrimazole.	Fungal infection [1F29-1F2F]	[3]
Fluconazole	DMOWZ6B	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fluconazole.	Fungal infection [1F29-1F2F]	[3]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ketoconazole.	Fungal infection [1F29-1F2F]	[3]
Atovaquone	DMY4UMW	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Atovaquone.	Fungal infection [1F29-1F2F]	[3]
Sunitinib	DMCBJSR	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[3]
Ramipril	DM2R68E	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ramipril.	Heart failure [BD10-BD1Z]	[3]
Interferon alfacon-1	DM90WJH	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon alfacon-1.	Hepatitis virus infection [1E50-1E51]	[3]
Lamivudine	DMI347A	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lamivudine.	Hepatitis virus infection [1E50-1E51]	[3]
Isoniazid	DM5JVS3	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[3]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[10]
Zidovudine	DM4KI7O	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zidovudine.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Stavudine	DM6DEK9	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Stavudine.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Nevirapine	DM6HX9B	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nevirapine.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Tipranavir	DM8HJX6	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Emtricitabine	DMBMUWZ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Emtricitabine.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Abacavir	DMMN36E	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Abacavir.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Darunavir	DMN3GCH	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Darunavir.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Maraviroc	DMTL94F	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Ritonavir	DMU764S	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ritonavir.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Simvastatin	DM30SGU	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Simvastatin.	Hyper-lipoproteinaemia [5C80]	[3]
Fluvastatin	DM4MDJY	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fluvastatin.	Hyper-lipoproteinaemia [5C80]	[3]
Pravastatin	DM6A0X7	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pravastatin.	Hyper-lipoproteinaemia [5C80]	[3]
Lovastatin	DM9OZWQ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lovastatin.	Hyper-lipoproteinaemia [5C80]	[3]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[3]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[12]
Rosuvastatin	DMMIQ7G	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Rosuvastatin.	Hyper-lipoproteinaemia [5C80]	[3]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[13]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[14]
Cerivastatin	DMXCM7H	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Cerivastatin.	Hyper-lipoproteinaemia [5C80]	[3]
Moexipril	DM26E4B	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Moexipril.	Hypertension [BA00-BA04]	[3]
Captopril	DM458UM	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Captopril.	Hypertension [BA00-BA04]	[3]
Trandolapril	DM4L6EU	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trandolapril.	Hypertension [BA00-BA04]	[3]
Methyldopa	DM5I621	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Methyldopa.	Hypertension [BA00-BA04]	[3]
Fosinopril	DM9NJ52	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Fosinopril.	Hypertension [BA00-BA04]	[3]
Enalapril	DMNFUZR	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Enalapril.	Hypertension [BA00-BA04]	[3]
Perindopril	DMOPZDT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Perindopril.	Hypertension [BA00-BA04]	[3]
Quinapril	DMR8H31	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Quinapril.	Hypertension [BA00-BA04]	[3]
Lisinopril	DMUOK4C	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lisinopril.	Hypertension [BA00-BA04]	[3]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Dipyridamole.	Hypertension [BA00-BA04]	[8]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[3]
Pirfenidone	DM6VZFQ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pirfenidone.	Idiopathic interstitial pneumonitis [CB03]	[3]
Vitamin B3	DMQVRZH	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Vitamin B3.	Inborn lipid metabolism error [5C52]	[3]
Givosiran	DM5PFIJ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[3]
Febuxostat	DMDEXQ0	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Febuxostat.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[3]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[8]
Ticlopidine	DMO946V	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ticlopidine.	Ischaemic/haemorrhagic stroke [8B20]	[8]
DTI-015	DMXZRW0	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and DTI-015.	Liver cancer [2C12]	[3]
Testosterone	DM7HUNW	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Testosterone.	Low bone mass disorder [FB83]	[3]
Crizotinib	DM4F29C	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Crizotinib.	Lung cancer [2C25]	[3]
Lurbinectedin	DMEFRTZ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lurbinectedin.	Lung cancer [2C25]	[3]
Alectinib	DMP1I6Y	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Alectinib.	Lung cancer [2C25]	[3]
BIBW 2992	DMTKD7Q	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and BIBW 2992.	Lung cancer [2C25]	[3]
Pralsetinib	DMWU0I2	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pralsetinib.	Lung cancer [2C25]	[3]
Capmatinib	DMYCXKL	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Capmatinib.	Lung cancer [2C25]	[3]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulphadoxine.	Malaria [1F40-1F45]	[3]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Idelalisib.	Mature B-cell leukaemia [2A82]	[15]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Clofarabine.	Mature B-cell lymphoma [2A85]	[16]
Blinatumomab	DMGECIJ	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Blinatumomab.	Mature B-cell lymphoma [2A85]	[3]
Vincristine	DMINOX3	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Vincristine.	Mature B-cell lymphoma [2A85]	[3]
Mercaptopurine	DMTM2IK	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[3]
Ponatinib	DMYGJQO	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ponatinib.	Mature B-cell lymphoma [2A85]	[3]
Cytarabine	DMZD5QR	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Cytarabine.	Mature B-cell lymphoma [2A85]	[3]
Vemurafenib	DM62UG5	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Vemurafenib.	Melanoma [2C30]	[3]
Ipilimumab	DMJTIYK	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ipilimumab.	Melanoma [2C30]	[3]
Interferon alfa-2B	DMWCQP4	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon alfa-2B.	Melanoma [2C30]	[3]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of PMID27977313-Compound-29 caused by Ethinyl estradiol mediated hepatotoxicity.	Menopausal disorder [GA30]	[4]
Danazol	DML8KTN	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Danazol.	Menstrual cycle bleeding disorder [GA20]	[3]
Exjade	DMHPRWG	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Exjade.	Mineral absorption/transport disorder [5C64]	[3]
Riluzole	DMECBWN	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Riluzole.	Motor neuron disease [8B60]	[3]
Carfilzomib	DM48K0X	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Carfilzomib.	Multiple myeloma [2A83]	[3]
Panobinostat	DM58WKG	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Panobinostat.	Multiple myeloma [2A83]	[3]
Lenalidomide	DM6Q7U4	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lenalidomide.	Multiple myeloma [2A83]	[3]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of PMID27977313-Compound-29 and Thalidomide.	Multiple myeloma [2A83]	[17]
Bortezomib	DMNO38U	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bortezomib.	Multiple myeloma [2A83]	[3]
Interferon beta-1a	DM1A6RV	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon beta-1a.	Multiple sclerosis [8A40]	[18]
Tecfidera	DM2OVDT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tecfidera.	Multiple sclerosis [8A40]	[3]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Siponimod.	Multiple sclerosis [8A40]	[4]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Fingolimod.	Multiple sclerosis [8A40]	[19]
Interferon beta-1b	DMCN61Z	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Interferon beta-1b.	Multiple sclerosis [8A40]	[18]
Pyrazinamide	DM4IF32	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Pyrazinamide.	Mycobacterium infection [1B10-1B21]	[3]
Nilotinib	DM7HXWT	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nilotinib.	Myeloproliferative neoplasm [2A20]	[3]
Imatinib	DM7RJXL	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Imatinib.	Myeloproliferative neoplasm [2A20]	[3]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Prasugrel.	Myocardial infarction [BA41-BA43]	[8]
Bupropion	DM5PCS7	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bupropion.	Nicotine use disorder [6C4A]	[3]
Entrectinib	DMMPTLH	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Entrectinib.	Non-small cell lung cancer [2C25]	[3]
Orlistat	DMRJSP8	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Orlistat.	Obesity [5B80-5B81]	[3]
Rofecoxib	DM3P5DA	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Rofecoxib.	Osteoarthritis [FA00-FA05]	[3]
Valdecoxib	DMAY7H4	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Valdecoxib.	Osteoarthritis [FA00-FA05]	[3]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Diclofenac.	Osteoarthritis [FA00-FA05]	[5]
Naproxen	DMZ5RGV	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Naproxen.	Osteoarthritis [FA00-FA05]	[8]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Aspirin.	Pain [MG30-MG3Z]	[8]
Etodolac	DM6WJO9	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Etodolac.	Pain [MG30-MG3Z]	[8]
Diflunisal	DM7EN8I	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Diflunisal.	Pain [MG30-MG3Z]	[8]
Ibuprofen	DM8VCBE	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ibuprofen.	Pain [MG30-MG3Z]	[8]
Nabumetone	DMAT2XH	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Nabumetone.	Pain [MG30-MG3Z]	[8]
Piroxicam	DMTK234	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Piroxicam.	Pain [MG30-MG3Z]	[8]
Acetaminophen	DMUIE76	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Acetaminophen.	Pain [MG30-MG3Z]	[3]
Tolcapone	DM8MNVO	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tolcapone.	Parkinsonism [8A00]	[3]
Doxycycline	DM7ICNU	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Doxycycline.	Periodontal disease [DA0C]	[3]
Ketorolac	DMI4EL5	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Ketorolac.	Postoperative inflammation [1A00-CA43]	[8]
Bromfenac	DMKB79O	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Bromfenac.	Postoperative inflammation [1A00-CA43]	[8]
ABIRATERONE	DM8V75C	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and ABIRATERONE.	Prostate cancer [2C82]	[3]
Nilutamide	DMFN07X	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nilutamide.	Prostate cancer [2C82]	[3]
Flutamide	DMK0O7U	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Flutamide.	Prostate cancer [2C82]	[3]
Bicalutamide	DMZMSPF	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bicalutamide.	Prostate cancer [2C82]	[3]
Acitretin	DM8BKU9	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Acitretin.	Psoriasis [EA90]	[3]
Infliximab	DMH7OIA	Major	Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Infliximab.	Psoriasis [EA90]	[20]
Bosentan	DMIOGBU	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Bosentan.	Pulmonary hypertension [BB01]	[3]
Axitinib	DMGVH6N	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Axitinib.	Renal cell carcinoma [2C90]	[3]
Sorafenib	DMS8IFC	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sorafenib.	Renal cell carcinoma [2C90]	[3]
Sulfadiazine	DMTW3R8	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfadiazine.	Rheumatic fever [1B40]	[3]
Salsalate	DM13P4C	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Salsalate.	Rheumatoid arthritis [FA20]	[8]
Meloxicam	DM2AR7L	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Meloxicam.	Rheumatoid arthritis [FA20]	[8]
Sulindac	DM2QHZU	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Sulindac.	Rheumatoid arthritis [FA20]	[8]
Tocilizumab	DM7J6OR	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Tocilizumab.	Rheumatoid arthritis [FA20]	[3]
Oxaprozin	DM9UB0P	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Oxaprozin.	Rheumatoid arthritis [FA20]	[8]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Flurbiprofen.	Rheumatoid arthritis [FA20]	[8]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of PMID27977313-Compound-29 and Golimumab.	Rheumatoid arthritis [FA20]	[20]
Sulfasalazine	DMICA9H	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfasalazine.	Rheumatoid arthritis [FA20]	[3]
Fenoprofen	DML5VQ0	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Fenoprofen.	Rheumatoid arthritis [FA20]	[8]
Sarilumab	DMOGNXY	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sarilumab.	Rheumatoid arthritis [FA20]	[3]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Leflunomide.	Rheumatoid arthritis [FA20]	[13]
Indomethacin	DMSC4A7	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Indomethacin.	Rheumatoid arthritis [FA20]	[8]
Tolmetin	DMWUIJE	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Tolmetin.	Rheumatoid arthritis [FA20]	[8]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of PMID27977313-Compound-29 when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[21]
Gefitinib	DM15F0X	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Gefitinib.	Solid tumour/cancer [2A00-2F9Z]	[3]
Larotrectinib	DM26CQR	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[3]
PDX-101	DM6OC53	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and PDX-101.	Solid tumour/cancer [2A00-2F9Z]	[3]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[9]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[4]
Norethindrone	DMTY169	Moderate	Decreased metabolism of PMID27977313-Compound-29 caused by Norethindrone mediated hepatotoxicity.	Solid tumour/cancer [2A00-2F9Z]	[4]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[3]
Disulfiram	DMCL2OK	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Disulfiram.	Substance abuse [6C40]	[3]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Naltrexone.	Substance abuse [6C40]	[22]
Zithromax	DMN4H2O	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Zithromax.	Syphilis [1A61-1A6Z]	[3]
Eltrombopag	DMOGFIX	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Eltrombopag.	Thrombocytopenia [3B64]	[3]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Caplacizumab.	Thrombocytopenia [3B64]	[8]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Apixaban.	Thrombosis [DB61-GB90]	[8]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Cangrelor.	Thrombosis [DB61-GB90]	[8]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Brilinta.	Thrombosis [DB61-GB90]	[8]
Dicumarol	DMFQCB1	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Dicumarol.	Thrombosis [DB61-GB90]	[8]
Clopidogrel	DMOL54H	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Clopidogrel.	Thrombosis [DB61-GB90]	[8]
Lenvatinib	DMB1IU4	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Lenvatinib.	Thyroid cancer [2D10]	[3]
Methimazole	DM25FL8	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Methimazole.	Thyrotoxicosis [5A02]	[3]
Propylthiouracil	DM6D7N8	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Propylthiouracil.	Thyrotoxicosis [5A02]	[3]
Trimetrexate	DMDEA85	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Trimetrexate.	Toxoplasmosis [1F57]	[3]
Ethambutol	DMR87LC	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Ethambutol.	Tuberculosis [1B10-1B12]	[3]
Nitrofurantoin	DM7PQIK	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Nitrofurantoin.	Urinary tract infection [GC08]	[3]
Sulfamethizole	DMGCHDS	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfamethizole.	Urinary tract infection [GC08]	[3]
Sulfisoxazole	DMXLT8C	Moderate	Increased risk of hepatotoxicity by the combination of PMID27977313-Compound-29 and Sulfisoxazole.	Urinary tract infection [GC08]	[3]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of PMID27977313-Compound-29 and Betrixaban.	Venous thromboembolism [BD72]	[8]
-----------


⏷ Show the Full List of 224 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Water	E00035	962	Solvent
Trisodium Phosphate	E00284	24243	Other agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Pegaspargase 750 units/vial injectable	750 units/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
2	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
3	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
4	Cerner Multum, Inc. "Australian Product Information.".
5	Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
6	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
7	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
8	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
11	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
12	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
13	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
14	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
15	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
16	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
17	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
18	Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
19	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
20	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
21	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
22	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.